Insurance Denied Lyme Disease Treatment? How to Appeal Extended Antibiotic and Persistent Symptom Denials

Lyme disease, caused by Borrelia burgdorferi infection, affects approximately 476,000 Americans annually according to CDC estimates. While most cases respond to standard 2–4 week antibiotic courses, a significant subset of patients develop persistent symptoms — Post-Treatment Lyme Disease Syndrome (PTLDS) or what many physicians and patients call "chronic Lyme disease." Treatment for these patients is one of the most contested areas in medicine, and insurance denials are both common and contentious.

If your insurer denied extended antibiotic therapy or other Lyme-related treatments, here is how to build the strongest possible appeal.

Why Insurers Deny Lyme Disease Treatment

The central conflict in Lyme disease coverage stems from a genuine disagreement between two major medical organizations about long-term treatment:

• IDSA guidelines (Infectious Diseases Society of America) — the 2006 guidelines (updated 2020 as a clinical practice guideline by IDSA/AAN/ACR) recommend 2–4 weeks of antibiotics for most cases and do not recommend prolonged antibiotic therapy for PTLDS, stating clinical trials have not shown benefit
• ILADS guidelines (International Lyme and Associated Diseases Society) — evidence-based guidelines recommending individualized, longer-course antibiotic therapy for patients with persistent symptoms, citing inadequate treatment in some cases

Insurers almost universally follow IDSA guidelines when denying claims. Common denial reasons include:

• Not medically necessary — citing IDSA guidelines as the sole clinical standard
• Experimental or investigational — categorizing extended antibiotic therapy as unproven
• Non-covered diagnosis — denial of "chronic Lyme disease" as a recognized diagnosis
• Specialty not recognized — denial of consultations with Lyme-literate physicians who may be out-of-network

Common denial codes: CO-50 (not medically necessary), CO-96 (non-covered charge), CO-57 (prior coverage not established), N-479 (benefit not applicable).

The IDSA vs. ILADS Conflict and How to Navigate It

The guidelines disagreement is real — but it does not mean insurers are automatically correct to deny all extended treatment. Courts and insurance regulators have found that when a genuine medical controversy exists, the insurer cannot simply pick one side and use it to deny care without further clinical analysis.

Key arguments to make in your appeal:

1. The patient's treating physician is the appropriate clinical authority. Courts have consistently recognized that a physician who has examined the patient and reviewed their history has more direct clinical knowledge than an insurer's reviewing physician who has not. Document your physician's clinical rationale in detail.

2. ILADS guidelines are legitimate evidence-based guidelines. They were published in a peer-reviewed journal (International Journal of Medical Sciences, 2014) and developed using a modified Delphi process. They are not fringe medicine.

3. No consensus means the insurer must exercise independent clinical judgment. An insurer cannot deny care solely because guidelines are contested — they must apply the standard of "generally accepted medical practice" with reference to the specific patient's circumstances.

Documenting a Lyme Disease Appeal

Confirm the diagnosis is properly coded. The ICD-10 codes for Lyme disease include:

• A69.20 — Lyme disease, unspecified
• A69.21 — Meningitis due to Lyme disease
• A69.22 — Other neurologic disorders in Lyme disease
• A69.23 — Arthritis due to Lyme disease
• A69.29 — Other conditions associated with Lyme disease

For persistent symptoms, G93.3 (postviral fatigue syndrome) or M79.3 (fibromyalgia) codes may apply to specific symptom clusters.

Document objective findings where possible. Serology (ELISA + Western blot using CDC two-tier criteria), clinical exam findings, and any co-infections (Babesia, Anaplasmosis) should be documented. For neurological symptoms, MRI or neuropsychological testing results strengthen the case.

Step-by-Step Appeal Strategy

Step 1: Obtain the full denial letter and the clinical criteria used. Identify whether the insurer cited IDSA guidelines specifically and whether they reviewed your actual medical records or simply conducted a paper review.

Step 2: Request a physician-to-physician review. Ask that the insurer's medical reviewer speak directly with your treating physician. Many states require this opportunity. A conversation between clinicians often resolves what paper reviews cannot.

Step 3: Submit a detailed letter from your treating physician. This letter should:

• Summarize the patient's clinical history, including tick exposure, initial presentation, and treatment history
• Describe the specific persistent symptoms and their functional impact
• Explain the clinical rationale for extended treatment under the specific circumstances
• Reference ILADS guidelines and the treating physician's expertise
• Address the IDSA position and explain why it does not apply to this patient's clinical situation

Step 4: Challenge "experimental" designations. Oral doxycycline and IV ceftriaxone (the most common agents for extended treatment) are both FDA-approved antibiotics with long safety records. The question is whether extended duration is appropriate — not whether the drugs themselves are experimental.

Step 5: File for External Independent Review: Complete Guide" class="auto-link">external review or contact your state insurance commissioner. In states like Connecticut, New York, Massachusetts, and California, Lyme disease treatment has received specific legislative attention. Cite any applicable state protections.

Supporting Evidence to Gather

• Serological test results (ELISA and CDC-compliant Western blot)
• Physician notes documenting persistent symptoms over time
• Neuropsychological testing or neurological consult notes
• Co-infection test results (Babesia, Ehrlichia, Bartonella)
• ILADS evidence-based guidelines (available at ilads.org)
• Treating physician's letter with specific clinical rationale
• Any state-level Lyme disease insurance protections

Fight Back With ClaimBack

Lyme disease patients are often dismissed and denied at every turn. ClaimBack helps you cut through the bureaucracy and submit an appeal grounded in clinical evidence and your physician's professional judgment.

Start your Lyme disease treatment appeal today

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Insurance Ombudsman Guide: How to File a Complaint